Understanding the Immunoenvironment of Primary Liver Cancer: A Histopathology Perspective

References

• Lokuhetty D, White VA, Watanabe R, Cree IA; World Health Organisation, International Agency for Research on Cancer. The 2019 WHO Classification of Tumours of the Digestive System. 5th ed. Lyon: International Agency for Research on Cancer; 2019.
   Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Sangro B, Sarobe P, Hervás-Stubbs S, Melero I. Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18(8):525–543. doi:10.1038/s41575-021-00438-0
   PubMed Web of Science ®Google Scholar
• Jeng K, Chang C, Jeng W, Sheen I, Jeng C. Heterogeneity of hepatocellular carcinoma contributes to cancer progression. Crit Rev Oncol Hematol. 2015;94(3):337–347. doi:10.1016/j.critrevonc.2015.01.009
   PubMed Web of Science ®Google Scholar
• Nguyen PHD, Ma S, Phua CZJ, et al. Intratumoural immune heterogeneity as a hallmark of tumour evolution and progression in hepatocellular carcinoma. Nat Commun. 2021;12(1):1–13.
   PubMed Web of Science ®Google Scholar
• Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: new trends. J Hepatol. 2020;72(2):250–261. doi:10.1016/j.jhep.2019.08.025
   PubMed Web of Science ®Google Scholar
• Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology. 2019;156(2):477–491.e1. doi:10.1053/j.gastro.2018.08.065
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–390. doi:10.1056/NEJMoa0708857
   PubMed Web of Science ®Google Scholar
• Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised Phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–1173. doi:10.1016/S0140-6736(18)30207-1
   PubMed Web of Science ®Google Scholar
• Rizzo A, Ricci AD, Gadaleta-Caldarola G, Brandi G. First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges. Expert Rev Gastroenterol Hepatol. 2021;15(11):1245–1251. doi:10.1080/17474124.2021.1973431
   PubMed Web of Science ®Google Scholar
• Yau T, Park J, Finn RS, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2022;23(1):77–90. doi:10.1016/S1470-2045(21)00604-5
   PubMed Web of Science ®Google Scholar
• Finn RS, Ryoo B, Merle P, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. JCO. 2020;38(3):193–202. doi:10.1200/JCO.19.01307
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–1905. doi:10.1056/NEJMoa1915745
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 2022;1(8):EVIDoa2100070. doi:10.1056/EVIDoa2100070
   PubMedGoogle Scholar
• Rizzo A, Ricci AD, Brandi G. Systemic adjuvant treatment in hepatocellular carcinoma: tempted to do something rather than nothing. Future Oncol. 2020;16(32):2587–2589. doi:10.2217/fon-2020-0669
   PubMed Web of Science ®Google Scholar
• De Lorenzo S, Tovoli F, Barbera MA, et al. Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: a proof of concept. Sci Rep. 2018;8(1):1–7. doi:10.1038/s41598-018-28337-6
   PubMed Web of Science ®Google Scholar
• Jenne CN, Kubes P. Immune surveillance by the liver. Nat Immunol. 2013;14(10):996–1006. doi:10.1038/ni.2691
   PubMed Web of Science ®Google Scholar
• Robinson MW, Harmon C, O’Farrelly C. Liver immunology and its role in inflammation and homeostasis. Cell Mol Immunol. 2016;13(3):267–276. doi:10.1038/cmi.2016.3
   PubMed Web of Science ®Google Scholar
• Prieto J, Melero I, Sangro B. Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2015;12(12):681–700. doi:10.1038/nrgastro.2015.173
   PubMed Web of Science ®Google Scholar
• Capece D, Fischietti M, Verzella D, et al. The inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumor-associated macrophages. Biomed Res Int. 2012;2013:e187204.
   PubMed Web of Science ®Google Scholar
• Ringelhan M, Pfister D, O’Connor T, Pikarsky E, Heikenwalder M. The immunology of hepatocellular carcinoma. Nat Immunol. 2018;19(3):222–232. doi:10.1038/s41590-018-0044-z
   PubMed Web of Science ®Google Scholar
• Chew V, Tow C, Teo M, et al. Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients. J Hepatol. 2010;52(3):370–379. doi:10.1016/j.jhep.2009.07.013
   PubMed Web of Science ®Google Scholar
• Sun C, Sun H, Xiao W, Zhang C, Tian Z. Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy. Acta Pharmacol Sin. 2015;36(10):1191–1199. doi:10.1038/aps.2015.41
   PubMed Web of Science ®Google Scholar
• Chew V, Chen J, Lee D, et al. Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma. Gut. 2012;61(3):427–438. doi:10.1136/gutjnl-2011-300509
   PubMed Web of Science ®Google Scholar
• Cai L, Zhang Z, Zhou L, et al. Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients. Clin Immunol. 2008;129(3):428–437. doi:10.1016/j.clim.2008.08.012
   PubMed Web of Science ®Google Scholar
• Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol. 2011;29(1):235–271. doi:10.1146/annurev-immunol-031210-101324
   PubMed Web of Science ®Google Scholar
• Wu Y, Kuang D, Pan W, et al. Monocyte/macrophage-elicited natural killer cell dysfunction in hepatocellular carcinoma is mediated by CD48/2B4 interactions. Hepatology. 2013;57(3):1107–1116. doi:10.1002/hep.26192
   PubMed Web of Science ®Google Scholar
• Pang Y, Zhang H, Peng J, et al. The immunosuppressive tumor microenvironment in hepatocellular carcinoma. Cancer Immunol Immunother. 2009;58(6):877–886. doi:10.1007/s00262-008-0603-5
   PubMed Web of Science ®Google Scholar
• Kamimura H, Yamagiwa S, Tsuchiya A, et al. Reduced NKG2D ligand expression in hepatocellular carcinoma correlates with early recurrence. J Hepatol. 2012;56(2):381–388. doi:10.1016/j.jhep.2011.06.017
   PubMed Web of Science ®Google Scholar
• Hou J, Zhang H, Sun B, Karin M. The immunobiology of hepatocellular carcinoma in humans and mice: basic concepts and therapeutic implications. J Hepatol. 2020;72(1):167–182. doi:10.1016/j.jhep.2019.08.014
   PubMed Web of Science ®Google Scholar
• Heymann F, Peusquens J, Ludwig-Portugall I, et al. Liver inflammation abrogates immunological tolerance induced by Kupffer cells. Hepatology. 2015;62(1):279–291. doi:10.1002/hep.27793
   PubMed Web of Science ®Google Scholar
• Tian Z, Hou X, Liu W, Han Z, Wei L. Macrophages and hepatocellular carcinoma. Cell Biosci. 2019;9. doi:10.1186/s13578-019-0342-7
   Web of Science ®Google Scholar
• Yeung OWH, Lo C, Ling C, et al. Alternatively activated (M2) macrophages promote tumour growth and invasiveness in hepatocellular carcinoma. J Hepatol. 2015;62(3):607–616. doi:10.1016/j.jhep.2014.10.029
   PubMed Web of Science ®Google Scholar
• Yu L, Ling Y, Wang H. Role of nonresolving inflammation in hepatocellular carcinoma development and progression. NPJ Precis Oncol. 2018;2(1):6. doi:10.1038/s41698-018-0048-z
   PubMed Web of Science ®Google Scholar
• Zhu X, Zhang J, Zhuang P, et al. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. JCO. 2008;26(16):2707–2716. doi:10.1200/JCO.2007.15.6521
   PubMed Web of Science ®Google Scholar
• Dong N, Shi X, Wang S, et al. M2 macrophages mediate sorafenib resistance by secreting HGF in a feed-forward manner in hepatocellular carcinoma. Br J Cancer. 2019;121(1):22–33. doi:10.1038/s41416-019-0482-x
   PubMed Web of Science ®Google Scholar
• Zhang Q, He Y, Luo N, et al. Landscape and dynamics of single immune cells in hepatocellular carcinoma. Cell. 2019;179(4):829–845.e20. doi:10.1016/j.cell.2019.10.003
   PubMed Web of Science ®Google Scholar
• Pagès F, Galon J, Dieu-Nosjean M, Tartour E, Sautès-Fridman C, Fridman W. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene. 2010;29(8):1093–1102. doi:10.1038/onc.2009.416
   PubMed Web of Science ®Google Scholar
• Zheng C, Zheng L, Yoo J, et al. Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing. Cell. 2017;169(7):1342–1356.e16. doi:10.1016/j.cell.2017.05.035
   PubMed Web of Science ®Google Scholar
• Zhou G, Sprengers D, Boor PPC, et al. Antibodies against immune checkpoint molecules restore functions of tumor-infiltrating T cells in hepatocellular carcinomas. Gastroenterology. 2017;153(4):1107–1119.e10. doi:10.1053/j.gastro.2017.06.017
   PubMed Web of Science ®Google Scholar
• Rowshanravan B, Halliday N, Sansom DM. CTLA-4: a moving target in immunotherapy. Blood. 2018;131(1):58–67. doi:10.1182/blood-2017-06-741033
   PubMed Web of Science ®Google Scholar
• Chen D, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1–10. doi:10.1016/j.immuni.2013.07.012
   PubMed Web of Science ®Google Scholar
• Garnelo M, Tan A, Her Z, et al. Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma. Gut. 2017;66(2):342–351. doi:10.1136/gutjnl-2015-310814
   PubMed Web of Science ®Google Scholar
• Shao Y, Lo CM, Ling CC, et al. Regulatory B cells accelerate hepatocellular carcinoma progression via CD40/CD154 signaling pathway. Cancer Lett. 2014;355(2):264–272. doi:10.1016/j.canlet.2014.09.026
   PubMed Web of Science ®Google Scholar
• Kessel A, Haj T, Peri R, et al. Human CD19+CD25high B regulatory cells suppress proliferation of CD4+ T cells and enhance Foxp3 and CTLA-4 expression in T-regulatory cells. Autoimmun Rev. 2012;11(9):670–677. doi:10.1016/j.autrev.2011.11.018
   PubMed Web of Science ®Google Scholar
• Zhang Z, Ma L, Goswami S, et al. Landscape of infiltrating B cells and their clinical significance in human hepatocellular carcinoma. OncoImmunology. 2019;8(4):e1571388. doi:10.1080/2162402X.2019.1571388
   PubMed Web of Science ®Google Scholar
• Schumacher TN, Thommen DS. Tertiary lymphoid structures in cancer. Science. 2022;375. doi:10.1126/science.abf9419
   Web of Science ®Google Scholar
• Sautès-Fridman C, Petitprez F, Calderaro J, Fridman WH. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer. 2019;19(6):307–325. doi:10.1038/s41568-019-0144-6
   PubMed Web of Science ®Google Scholar
• Fridman WH, Zitvogel L, Sautès–Fridman C, Kroemer G. The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol. 2017;14(12):717–734. doi:10.1038/nrclinonc.2017.101
   PubMed Web of Science ®Google Scholar
• Cabrita R, Lauss M, Sanna A, et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature. 2020;577(7791):561–565. doi:10.1038/s41586-019-1914-8
   PubMed Web of Science ®Google Scholar
• Di Caro G, Bergomas F, Grizzi F, et al. Occurrence of tertiary lymphoid tissue is associated with T-cell infiltration and predicts better prognosis in early-stage colorectal cancers. Clin Cancer Res. 2014;20(8):2147–2158. doi:10.1158/1078-0432.CCR-13-2590
   PubMed Web of Science ®Google Scholar
• Liu X, Tsang JYS, Hlaing T, et al. Distinct tertiary lymphoid structure associations and their prognostic relevance in HER2 positive and negative breast cancers. Oncologist. 2017;22(11):1316–1324. doi:10.1634/theoncologist.2017-0029
   PubMed Web of Science ®Google Scholar
• Dieu-Nosjean M, Goc J, Giraldo NA, Sautès-Fridman C, Fridman WH. Tertiary lymphoid structures in cancer and beyond. Trends Immunol. 2014;35(11):571–580. doi:10.1016/j.it.2014.09.006
   PubMed Web of Science ®Google Scholar
• Colbeck EJ, Ager A, Gallimore A, Jones GW. Tertiary lymphoid structures in cancer: drivers of antitumor immunity, immunosuppression, or bystander sentinels in disease? Front Immunol. 2017;8. doi:10.3389/fimmu.2017.01830
   PubMed Web of Science ®Google Scholar
• Calderaro J, Petitprez F, Becht E, et al. Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma. J Hepatol. 2019;70(1):58–65. doi:10.1016/j.jhep.2018.09.003
   PubMed Web of Science ®Google Scholar
• Li H, Wang J, Liu H, et al. Existence of intratumoral tertiary lymphoid structures is associated with immune cells infiltration and predicts better prognosis in early-stage hepatocellular carcinoma. Aging. 2020;12(4):3451–3472. doi:10.18632/aging.102821
   PubMedGoogle Scholar
• Li H, Liu H, Fu H, et al. Peritumoral tertiary lymphoid structures correlate with protective immunity and improved prognosis in patients with hepatocellular carcinoma. Front Immunol. 2021;12:648812.
   PubMed Web of Science ®Google Scholar
• Finkin S, Yuan D, Stein I, et al. Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma. Nat Immunol. 2015;16(12):1235–1244. doi:10.1038/ni.3290
   PubMed Web of Science ®Google Scholar
• Hoshida Y, Nijman SMB, Kobayashi M, et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res. 2009;69(18):7385–7392. doi:10.1158/0008-5472.CAN-09-1089
   PubMed Web of Science ®Google Scholar
• Boyault S, Rickman DS, de Reyniès A, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology. 2007;45(1):42–52. doi:10.1002/hep.21467
   PubMed Web of Science ®Google Scholar
• Kudo M. Limited impact of anti-PD-1/PD-L1 monotherapy for hepatocellular carcinoma. LIC. 2020;9(6):629–639.
   Google Scholar
• Kurebayashi Y, Ojima H, Tsujikawa H, et al. Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification. Hepatology. 2018;68(3):1025–1041. doi:10.1002/hep.29904
   PubMed Web of Science ®Google Scholar
• Calderaro J, Rousseau B, Amaddeo G, et al. Programmed death ligand 1 expression in hepatocellular carcinoma: relationship with clinical and pathological features. Hepatology. 2016;64(6):2038–2046. doi:10.1002/hep.28710
   PubMed Web of Science ®Google Scholar
• Foerster F, Hess M, Gerhold-Ay A, et al. The immune contexture of hepatocellular carcinoma predicts clinical outcome. Sci Rep. 2018;8(1):1–11. doi:10.1038/s41598-018-21937-2
   PubMed Web of Science ®Google Scholar
• Sia D, Jiao Y, Martinez-Quetglas I, et al. Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features. Gastroenterology. 2017;153(3):812–826. doi:10.1053/j.gastro.2017.06.007
   PubMed Web of Science ®Google Scholar
• Shimada S, Mogushi K, Akiyama Y, et al. Comprehensive molecular and immunological characterization of hepatocellular carcinoma. EBioMedicine. 2019;40:457–470. doi:10.1016/j.ebiom.2018.12.058
   PubMed Web of Science ®Google Scholar
• Kurebayashi Y, Kubota N, Sakamoto M. Immune microenvironment of hepatocellular carcinoma, intrahepatic cholangiocarcinoma and liver metastasis of colorectal adenocarcinoma: relationship with histopathological and molecular classifications. Hepatol Res. 2021;51(1):5–18. doi:10.1111/hepr.13539
   PubMed Web of Science ®Google Scholar
• Zhang Q, Lou Y, Yang J, et al. Integrated multiomic analysis reveals comprehensive tumour heterogeneity and novel immunophenotypic classification in hepatocellular carcinomas. Gut. 2019;68(11):2019–2031. doi:10.1136/gutjnl-2019-318912
   PubMed Web of Science ®Google Scholar
• Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label Phase 2 trial. Lancet Oncol. 2018;19(7):940–952. doi:10.1016/S1470-2045(18)30351-6
   PubMed Web of Science ®Google Scholar
• Xue R, Li R, Guo H, et al. Variable intra-tumor genomic heterogeneity of multiple lesions in patients with hepatocellular carcinoma. Gastroenterology. 2016;150(4):998–1008. doi:10.1053/j.gastro.2015.12.033
   PubMed Web of Science ®Google Scholar
• Vij M, Calderaro J. Pathologic and molecular features of hepatocellular carcinoma: an update. World J Hepatol. 2021;13(4):393–410. doi:10.4254/wjh.v13.i4.393
   PubMed Web of Science ®Google Scholar
• Calderaro J, Ziol M, Paradis V, Zucman-Rossi J. Molecular and histological correlations in liver cancer. J Hepatol. 2019;71(3):616–630. doi:10.1016/j.jhep.2019.06.001
   PubMed Web of Science ®Google Scholar
• Wada Y, Nakashima O, Kutami R, Yamamoto O, Kojiro M. Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration. Hepatology. 1998;27(2):407–414. doi:10.1002/hep.510270214
   PubMed Web of Science ®Google Scholar
• Chan AWH, Tong JHM, Pan Y, et al. Lymphoepithelioma-like hepatocellular carcinoma: an uncommon variant of hepatocellular carcinoma with favorable outcome. Am J Surg Pathol. 2015;39(3):304–312. doi:10.1097/PAS.0000000000000376
   PubMed Web of Science ®Google Scholar
• Salomao M, Remotti H, Vaughan R, Siegel AB, Lefkowitch JH, Moreira RK. The steatohepatitic variant of hepatocellular carcinoma and its association with underlying steatohepatitis. Hum Pathol. 2012;43(5):737–746. doi:10.1016/j.humpath.2011.07.005
   PubMed Web of Science ®Google Scholar
• Salomao M, Yu WM, Brown RS, Emond JC, Lefkowitch JH. Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH. Am J Surg Pathol. 2010;34(11):1630–1636. doi:10.1097/PAS.0b013e3181f31caa
   PubMed Web of Science ®Google Scholar
• Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology. 2010;51(5):1820–1832. doi:10.1002/hep.23594
   PubMed Web of Science ®Google Scholar
• Calderaro J, Couchy G, Imbeaud S, et al. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. J Hepatol. 2017;67(4):727–738. doi:10.1016/j.jhep.2017.05.014
   PubMed Web of Science ®Google Scholar
• Ziol M, Poté N, Amaddeo G, et al. Macrotrabecular-massive hepatocellular carcinoma: a distinctive histological subtype with clinical relevance. Hepatology. 2018;68(1):103–112. doi:10.1002/hep.29762
   PubMed Web of Science ®Google Scholar
• Calderaro J, Meunier L, Nguyen CT, et al. ESM1 as a marker of macrotrabecular-massive hepatocellular carcinoma. Clin Cancer Res. 2019;25(19):5859–5865. doi:10.1158/1078-0432.CCR-19-0859
   PubMed Web of Science ®Google Scholar
• Nagata H, Komatsu S, Takaki W, et al. Granulocyte colony-stimulating factor-producing hepatocellular carcinoma with abrupt changes. World J Clin Oncol. 2016;7(5):380–386. doi:10.5306/wjco.v7.i5.380
   PubMedGoogle Scholar
• Araki K, Kishihara F, Takahashi K, et al. Hepatocellular carcinoma producing a granulocyte colony-stimulating factor: report of a resected case with a literature review. Liver Int. 2007;27(5):716–721. doi:10.1111/j.1478-3231.2007.01468.x
   PubMed Web of Science ®Google Scholar
• Torbenson MS. Morphologic subtypes of hepatocellular carcinoma. Gastroenterol Clin North Am. 2017;46(2):365–391. doi:10.1016/j.gtc.2017.01.009
   PubMed Web of Science ®Google Scholar
• Ross HM, Daniel HD, Vivekanandan P, et al. Fibrolamellar carcinomas are positive for CD68. Mod Pathol. 2011;24(3):390–395. doi:10.1038/modpathol.2010.207
   PubMed Web of Science ®Google Scholar
• Ward SC, Huang J, Tickoo SK, Thung SN, Ladanyi M, Klimstra DS. Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile duct differentiation. Mod Pathol. 2010;23(9):1180–1190. doi:10.1038/modpathol.2010.105
   PubMed Web of Science ®Google Scholar
• Honeyman JN, Simon EP, Robine N, et al. Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. Science. 2014;343:1010–1014. doi:10.1126/science.1249484
   PubMed Web of Science ®Google Scholar
• Vyas M, Hechtman JF, Zhang Y, et al. DNAJB1-PRKACA fusions occur in oncocytic pancreatic and biliary neoplasms and are not specific for fibrolamellar hepatocellular carcinoma. Mod Pathol. 2020;33(4):648–656. doi:10.1038/s41379-019-0398-2
   PubMed Web of Science ®Google Scholar
• Kim AK, Gani F, Layman AJ, et al. Multiple immune-suppressive mechanisms in fibrolamellar carcinoma. Cancer Immunol Res. 2019;7(5):805–812. doi:10.1158/2326-6066.CIR-18-0499
   PubMed Web of Science ®Google Scholar
• Murtha-Lemekhova A, Fuchs J, Schulz E, et al. Scirrhous hepatocellular carcinoma: systematic review and pooled data analysis of clinical, radiological, and histopathological features. J Hepatocell Carcinoma. 2021;8:1269–1279. doi:10.2147/JHC.S328198
   PubMed Web of Science ®Google Scholar
• Kim Y, Rhee H, Yoo JE, et al. Tumour epithelial and stromal characteristics of hepatocellular carcinomas with abundant fibrous stroma: fibrolamellar versus scirrhous hepatocellular carcinoma. Histopathology. 2017;71(2):217–226. doi:10.1111/his.13219
   PubMed Web of Science ®Google Scholar
• Kurogi M, Nakashima O, Miyaaki H, Fujimoto M, Kojiro M. Clinicopathological study of scirrhous hepatocellular carcinoma. J Gastroenterol Hepatol. 2006;21(9):1470–1477. doi:10.1111/j.1440-1746.2006.04372.x
   PubMed Web of Science ®Google Scholar
• Wood LD, Heaphy CM, Daniel HD, et al. Chromophobe hepatocellular carcinoma with abrupt anaplasia: a proposal for a new subtype of hepatocellular carcinoma with unique morphological and molecular features. Mod Pathol. 2013;26(12):1586–1593. doi:10.1038/modpathol.2013.68
   PubMed Web of Science ®Google Scholar
• Kang HJ, Oh J, Kim YW, et al. Clinicopathological and molecular characterization of chromophobe hepatocellular carcinoma. Liver Int. 2021;41(10):2499–2510. doi:10.1111/liv.14975
   PubMed Web of Science ®Google Scholar
• Dilley RL, Greenberg RA. ALTernative telomere maintenance and cancer. Trends Cancer. 2015;1(2):145–156. doi:10.1016/j.trecan.2015.07.007
   PubMed Web of Science ®Google Scholar
• Zhang J, Zou L. Alternative lengthening of telomeres: from molecular mechanisms to therapeutic outlooks. Cell Biosci. 2020;10. doi:10.1186/s13578-020-00391-6
   Web of Science ®Google Scholar
• Li T, Fan J, Qin L, et al. Risk factors, prognosis, and management of early and late intrahepatic recurrence after resection of primary clear cell carcinoma of the liver. Ann Surg Oncol. 2011;18(7):1955–1963. doi:10.1245/s10434-010-1540-z
   PubMed Web of Science ®Google Scholar
• Lee JH, Shin DH, Park WY, et al. IDH1 R132C mutation is detected in clear cell hepatocellular carcinoma by pyrosequencing. World J Surg Oncol. 2017;15. doi:10.1186/s12957-017-1144-1
   Web of Science ®Google Scholar
• Yang H, Lu S, Liaw Y, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002;347(3):168–174. doi:10.1056/NEJMoa013215
   PubMed Web of Science ®Google Scholar
• Saito I, Miyamura T, Ohbayashi A, et al. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci U S A. 1990;87(17):6547–6549. doi:10.1073/pnas.87.17.6547
   PubMed Web of Science ®Google Scholar
• El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(6):1264–1273.e1. doi:10.1053/j.gastro.2011.12.061
   PubMed Web of Science ®Google Scholar
• Lim CJ, Lee YH, Pan L, et al. Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma. Gut. 2019;68(5):916–927. doi:10.1136/gutjnl-2018-316510
   PubMed Web of Science ®Google Scholar
• Ma C, Kesarwala AH, Eggert T, et al. NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis. Nature. 2016;531(7593):253–257. doi:10.1038/nature16969
   PubMed Web of Science ®Google Scholar
• Wolf MJ, Adili A, Piotrowitz K, et al. Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes. Cancer Cell. 2014;26(4):549–564. doi:10.1016/j.ccell.2014.09.003
   PubMed Web of Science ®Google Scholar
• van der Windt DJ, Sud V, Zhang H, et al. Neutrophil extracellular traps promote inflammation and development of hepatocellular carcinoma in nonalcoholic steatohepatitis. Hepatology. 2018;68(4):1347–1360. doi:10.1002/hep.29914
   PubMed Web of Science ®Google Scholar
• Oquiñena S, Guillen-Grima F, Iñarrairaegui M, Zozaya JM, Sangro B. Spontaneous regression of hepatocellular carcinoma: a systematic review. Eur J Gastroenterol Hepatol. 2009;21(3):254–257. doi:10.1097/MEG.0b013e328324b6a2
   PubMed Web of Science ®Google Scholar
• Cole WH, Everson TC. Spontaneous regression of cancer: preliminary report. Ann Surg. 1956;144(3):366–383. doi:10.1097/00000658-195609000-00007
   PubMed Web of Science ®Google Scholar
• Sakamaki A, Kamimura K, Abe S, et al. Spontaneous regression of hepatocellular carcinoma: a mini-review. World J Gastroenterol. 2017;23(21):3797–3804. doi:10.3748/wjg.v23.i21.3797
   PubMed Web of Science ®Google Scholar
• Huz JI, Melis M, Sarpel U. Spontaneous regression of hepatocellular carcinoma is most often associated with tumour hypoxia or a systemic inflammatory response. HPB. 2012;14(8):500–505. doi:10.1111/j.1477-2574.2012.00478.x
   PubMed Web of Science ®Google Scholar
• McCaughan GW, Bilous MJ, Gallagher ND. Long-term survival with tumor regression in androgen-induced liver tumors. Cancer. 1985;56(11):2622–2626. doi:10.1002/1097-0142(19851201)56:11<2622::AID-CNCR2820561115>3.0.CO;2-0
   PubMed Web of Science ®Google Scholar
• Abiru S, Kato Y, Hamasaki K, Nakao K, Nakata K, Eguchi K. Spontaneous regression of hepatocellular carcinoma associated with elevated levels of interleukin 18. Am J Gastroenterol. 2002;97(3):774–775. doi:10.1111/j.1572-0241.2002.05580.x
   PubMed Web of Science ®Google Scholar
• Ohba K, Omagari K, Nakamura T, et al. Abscopal regression of hepatocellular carcinoma after radiotherapy for bone metastasis. Gut. 1998;43(4):575–577. doi:10.1136/gut.43.4.575
   PubMed Web of Science ®Google Scholar
• Jozuka H, Jozuka E, Suzuki M, Takeuchi S, Takatsu Y. Psycho-neuro-immunological treatment of hepatocellular carcinoma with major depression--A single case report. Curr Med Res Opin. 2003;19(1):59–63. doi:10.1185/030079902125001362
   PubMed Web of Science ®Google Scholar
• Arjunan V, Hansen A, Deutzmann A, Sze DY, Dhanasekaran R. Spontaneous regression of hepatocellular carcinoma: when the immune system stands up to cancer. Hepatology. 2021;73(4):1611–1614. doi:10.1002/hep.31489
   PubMed Web of Science ®Google Scholar
• Pectasides E, Miksad R, Pyatibrat S, Srivastava A, Bullock A. Spontaneous regression of hepatocellular carcinoma with multiple lung metastases: a case report and review of the literature. Dig Dis Sci. 2016;61(9):2749–2754. doi:10.1007/s10620-016-4141-2
   PubMed Web of Science ®Google Scholar
• Heianna J, Miyauchi T, Suzuki T, Ishida H, Hashimoto M, Watarai J. Spontaneous regression of multiple lung metastases following regression of hepatocellular carcinoma after transcatheter arterial embolization. A case report. Hepatogastroenterology. 2007;54(77):1560–1562.
   PubMedGoogle Scholar
• Lendvai G, Szekerczés T, Illyés I, et al. Cholangiocarcinoma: classification, histopathology and molecular carcinogenesis. Pathol Oncol Res. 2020;26(1):3–15. doi:10.1007/s12253-018-0491-8
   PubMed Web of Science ®Google Scholar
• Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: epidemiology and risk factors. Liver Int. 2019;39(S1):19–31. doi:10.1111/liv.14095
   PubMed Web of Science ®Google Scholar
• Sripa B, Kaewkes S, Sithithaworn P, et al. Liver fluke induces cholangiocarcinoma. PLoS Med. 2007;4(7):e201. doi:10.1371/journal.pmed.0040201
   PubMed Web of Science ®Google Scholar
• Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 2013;145(6):1215–1229. doi:10.1053/j.gastro.2013.10.013
   PubMed Web of Science ®Google Scholar
• Bragazzi MC, Ridola L, Safarikia S, et al. New insights into cholangiocarcinoma: multiple stems and related cell lineages of origin. Ann Gastroenterol. 2018;31(1):42–55. doi:10.20524/aog.2017.0209
   PubMed Web of Science ®Google Scholar
• Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology. 2011;54(1):173–184. doi:10.1002/hep.24351
   PubMed Web of Science ®Google Scholar
• Guedj N, Blaise L, Cauchy F, Albuquerque M, Soubrane O, Paradis V. Prognostic value of desmoplastic stroma in intrahepatic cholangiocarcinoma. Mod Pathol. 2021;34(2):408–416. doi:10.1038/s41379-020-00656-y
   PubMed Web of Science ®Google Scholar
• Comito G, Giannoni E, Segura CP, et al. Cancer-associated fibroblasts and M2-polarized macrophages synergize during prostate carcinoma progression. Oncogene. 2014;33(19):2423–2431. doi:10.1038/onc.2013.191
   PubMed Web of Science ®Google Scholar
• Gentilini A, Pastore M, Marra F, Raggi C. The role of stroma in cholangiocarcinoma: the intriguing interplay between fibroblastic component, immune cell subsets and tumor epithelium. Int J Mol Sci. 2018;19(10):2885. doi:10.3390/ijms19102885
   PubMed Web of Science ®Google Scholar
• Hasita H, Komohara Y, Okabe H, et al. Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma. Cancer Sci. 2010;101(8):1913–1919. doi:10.1111/j.1349-7006.2010.01614.x
   PubMed Web of Science ®Google Scholar
• Whiteside TL. What are regulatory T cells (treg) regulating in cancer and why? Semin Cancer Biol. 2012;22(4):327–334. doi:10.1016/j.semcancer.2012.03.004
   PubMed Web of Science ®Google Scholar
• Zhang M, Yang H, Wan L, et al. Single-cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinoma. J Hepatol. 2020;73(5):1118–1130. doi:10.1016/j.jhep.2020.05.039
   PubMed Web of Science ®Google Scholar
• Goeppert B, Frauenschuh L, Zucknick M, et al. Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer. Br J Cancer. 2013;109(10):2665–2674. doi:10.1038/bjc.2013.610
   PubMed Web of Science ®Google Scholar
• Liu D, Heij LR, Czigany Z, et al. The role of tumor-infiltrating lymphocytes in cholangiocarcinoma. J Exp Clin Cancer Res. 2022;41(1):127. doi:10.1186/s13046-022-02340-2
   PubMed Web of Science ®Google Scholar
• Yugawa K, Itoh S, Yoshizumi T, et al. Prognostic impact of tumor microvessels in intrahepatic cholangiocarcinoma: association with tumor-infiltrating lymphocytes. Mod Pathol. 2021;34(4):798–807. doi:10.1038/s41379-020-00702-9
   PubMed Web of Science ®Google Scholar
• Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557–588. doi:10.1038/s41575-020-0310-z
   PubMed Web of Science ®Google Scholar
• Graham RP, Barr Fritcher EG, Pestova E, et al. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. Hum Pathol. 2014;45(8):1630–1638. doi:10.1016/j.humpath.2014.03.014
   PubMed Web of Science ®Google Scholar
• Borger DR, Tanabe KK, Fan KC, et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist. 2012;17(1):72–79. doi:10.1634/theoncologist.2011-0386
   PubMed Web of Science ®Google Scholar
• Yoon JG, Kim MH, Jang M, et al. Molecular characterization of biliary tract cancer predicts chemotherapy and programmed death 1/programmed death-ligand 1 blockade responses. Hepatology. 2021;74(4):1914–1931. doi:10.1002/hep.31862
   PubMed Web of Science ®Google Scholar
• Wang J, Dong M, Xu Z, et al. Notch2 controls hepatocyte-derived cholangiocarcinoma formation in mice. Oncogene. 2018;37(24):3229–3242. doi:10.1038/s41388-018-0188-1
   PubMed Web of Science ®Google Scholar
• Guest RV, Boulter L, Kendall TJ, et al. Cell lineage tracing reveals a biliary origin of intrahepatic cholangiocarcinoma. Cancer Res. 2014;74(4):1005–1010. doi:10.1158/0008-5472.CAN-13-1911
   PubMed Web of Science ®Google Scholar
• Komuta M, Spee B, Vander Borght S, et al. Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. Hepatology. 2008;47(5):1544–1556. doi:10.1002/hep.22238
   PubMed Web of Science ®Google Scholar
• Andersen JB, Spee B, Blechacz BR, et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology. 2012;142(4):1021–1031.e15. doi:10.1053/j.gastro.2011.12.005
   PubMed Web of Science ®Google Scholar
• Cardinale V, Renzi A, Carpino G, et al. Profiles of cancer stem cell subpopulations in cholangiocarcinomas. Am J Pathol. 2015;185(6):1724–1739. doi:10.1016/j.ajpath.2015.02.010
   PubMed Web of Science ®Google Scholar
• Carapeto F, Bozorgui B, Shroff RT, et al. The immunogenomic landscape of resected intrahepatic cholangiocarcinoma. Hepatology. 2022;75(2):297–308. doi:10.1002/hep.32150
   PubMed Web of Science ®Google Scholar
• Piha-Paul SA, Oh D, Ueno M, et al. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies. Int J Cancer. 2020;147(8):2190–2198. doi:10.1002/ijc.33013
   PubMed Web of Science ®Google Scholar
• Sia D, Hoshida Y, Villanueva A, et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology. 2013;144(4):829–840. doi:10.1053/j.gastro.2013.01.001
   PubMed Web of Science ®Google Scholar
• Job S, Rapoud D, Santos AD, et al. Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma. Hepatology. 2020;72(3):965–981. doi:10.1002/hep.31092
   PubMed Web of Science ®Google Scholar
• Fontugne J, Augustin J, Pujals A, et al. PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma. Oncotarget. 2017;8(15):24644–24651. doi:10.18632/oncotarget.15602
   PubMedGoogle Scholar
• Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18(3):197–218. doi:10.1038/s41573-018-0007-y
   PubMed Web of Science ®Google Scholar
• Oishi N, Kumar MR, Roessler S, et al. Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma. Hepatology. 2012;56(5):1792–1803. doi:10.1002/hep.25890
   PubMed Web of Science ®Google Scholar
• Ding G, Ma J, Yun J, et al. Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma. J Hepatol. 2022;76(3):608–618. doi:10.1016/j.jhep.2021.10.030
   PubMed Web of Science ®Google Scholar
• Martin-Serrano MA, Kepecs B, Torres-Martin M, et al. Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications. Gut. 2022;gutjnl-2021–326514. doi:10.1136/gutjnl-2021-326514
   Web of Science ®Google Scholar
• Banales JM, Cardinale V, Carpino G, et al. Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European network for the study of cholangiocarcinoma (ENS-CCA). Nat Rev. 2016;13(5):261–280. doi:10.1038/nrgastro.2016.51
   Google Scholar
• Kitano Y, Okabe H, Yamashita Y, et al. Tumour-infiltrating inflammatory and immune cells in patients with extrahepatic cholangiocarcinoma. Br J Cancer. 2018;118(2):171–180. doi:10.1038/bjc.2017.401
   PubMed Web of Science ®Google Scholar
• Lim YJ, Koh J, Kim K, et al. High ratio of programmed cell death protein 1 (PD-1)+/CD8+ tumor-infiltrating lymphocytes identifies a poor prognostic subset of extrahepatic bile duct cancer undergoing surgery plus adjuvant chemoradiotherapy. Radiother Oncol. 2015;117(1):165–170. doi:10.1016/j.radonc.2015.07.003
   PubMed Web of Science ®Google Scholar
• Walter D, Herrmann E, Schnitzbauer AA, et al. PD-L1 expression in extrahepatic cholangiocarcinoma. Histopathology. 2017;71(3):383–392. doi:10.1111/his.13238
   PubMed Web of Science ®Google Scholar
• Montal R, Sia D, Montironi C, et al. Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma. J Hepatol. 2020;73(2):315–327. doi:10.1016/j.jhep.2020.03.008
   PubMed Web of Science ®Google Scholar
• Goodman ZD, Ishak KG, Langloss JM, Sesterhenn IA, Rabin L. Combined hepatocellular-cholangiocarcinoma. A histologic and immunohistochemical study. Cancer. 1985;55(1):124–135. doi:10.1002/1097-0142(19850101)55:1<124::AID-CNCR2820550120>3.0.CO;2-Z
   PubMed Web of Science ®Google Scholar
• Kassahun WT, Hauss J. Management of combined hepatocellular and cholangiocarcinoma. Int J Clin Pract. 2008;62(8):1271–1278. doi:10.1111/j.1742-1241.2007.01694.x
   PubMed Web of Science ®Google Scholar
• Yeh MM. Pathology of combined hepatocellular-cholangiocarcinoma. J Gastroenterol Hepatol. 2010;25(9):1485–1492. doi:10.1111/j.1440-1746.2010.06430.x
   PubMed Web of Science ®Google Scholar
• Sapisochin G, Fidelman N, Roberts JP, Yao FY. Mixed hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma in patients undergoing transplantation for hepatocellular carcinoma. Liver Transplant. 2011;17(8):934–942. doi:10.1002/lt.22307
   PubMed Web of Science ®Google Scholar
• Lunsford KE, Court C, Lee YS, et al. Propensity-matched analysis of patients with mixed hepatocellular-cholangiocarcinoma and hepatocellular carcinoma undergoing liver transplantation. Liver Transplant. 2018;24(10):1384–1397. doi:10.1002/lt.25058
   PubMed Web of Science ®Google Scholar
• Garancini M, Goffredo P, Pagni F, et al. Combined hepatocellular-cholangiocarcinoma: a population-level analysis of an uncommon primary liver tumor. Liver Transplant. 2014;20(8):952–959. doi:10.1002/lt.23897
   PubMed Web of Science ®Google Scholar
• Nguyen CT, Caruso S, Maille P, et al. Immune profiling of combined hepatocellular- cholangiocarcinoma reveals distinct subtypes and activation of gene signatures predictive of response to immunotherapy. Clin Cancer Res. 2022;28(3):540–551. doi:10.1158/1078-0432.CCR-21-1219
   PubMed Web of Science ®Google Scholar
• Lu S, Stein JE, Rimm DL, et al. Comparison of biomarker modalities for predicting response to PD-1/PD-L1 checkpoint blockade: a systematic review and meta-analysis. JAMA Oncol. 2019;5(8):1195–1204. doi:10.1001/jamaoncol.2019.1549
   PubMed Web of Science ®Google Scholar
• Stack EC, Wang C, Roman KA, Hoyt CC. Multiplexed immunohistochemistry, imaging, and quantitation: a review, with an assessment of tyramide signal amplification, multispectral imaging and multiplex analysis. Methods. 2014;70(1):46–58. doi:10.1016/j.ymeth.2014.08.016
   PubMed Web of Science ®Google Scholar
• Gerner M, Kastenmuller W, Ifrim I, Kabat J, Germain R. Histo-cytometry: a method for highly multiplex quantitative tissue imaging analysis applied to dendritic cell subset microanatomy in lymph nodes. Immunity. 2012;37(2):364–376. doi:10.1016/j.immuni.2012.07.011
   PubMed Web of Science ®Google Scholar
• Li W, Germain RN, Gerner MY. Multiplex, quantitative cellular analysis in large tissue volumes with clearing-enhanced 3D microscopy (Ce3D). Proc Natl Acad Sci U S A. 2017;114(35):E7321–E7330. doi:10.1073/pnas.1708981114
   PubMed Web of Science ®Google Scholar
• Widodo SS, Hutchinson RA, Fang Y, et al. Toward precision immunotherapy using multiplex immunohistochemistry and in silico methods to define the tumor immune microenvironment. Cancer Immunol Immunother. 2021;70(7):1811–1820. doi:10.1007/s00262-020-02801-7
   PubMed Web of Science ®Google Scholar
• Sabdyusheva Litschauer I, Becker K, Saghafi S, et al. 3D histopathology of human tumours by fast clearing and ultramicroscopy. Sci Rep. 2020;10(1):1–16. doi:10.1038/s41598-020-71737-w
   PubMed Web of Science ®Google Scholar
• Weinstein RS. Prospects for telepathology. Hum Pathol. 1986;17(5):433–434. doi:10.1016/S0046-8177(86)80028-4
   PubMed Web of Science ®Google Scholar
• Pallua JD, Brunner A, Zelger B, Schirmer M, Haybaeck J. The future of pathology is digital. Pathology. 2020;216(9):153040. doi:10.1016/j.prp.2020.153040
   Web of Science ®Google Scholar
• Araújo ALD, Arboleda LPA, Palmier NR, et al. The performance of digital microscopy for primary diagnosis in human pathology: a systematic review. Virchows Arch. 2019;474(3):269–287. doi:10.1007/s00428-018-02519-z
   PubMed Web of Science ®Google Scholar
• Fuchs TJ, Buhmann JM. Computational pathology: challenges and promises for tissue analysis. Comput Med Imaging Graph. 2011;35(7):515–530. doi:10.1016/j.compmedimag.2011.02.006
   PubMed Web of Science ®Google Scholar
• van der Laak J, Litjens G, Ciompi F. Deep learning in histopathology: the path to the clinic. Nat Med. 2021;27(5):775–784. doi:10.1038/s41591-021-01343-4
   PubMed Web of Science ®Google Scholar
• Bera K, Schalper KA, Rimm DL, Velcheti V, Madabhushi A. Artificial intelligence in digital pathology — new tools for diagnosis and precision oncology. Nat Rev Clin Oncol. 2019;16(11):703–715. doi:10.1038/s41571-019-0252-y
   PubMed Web of Science ®Google Scholar
• Niazi MKK, Parwani AV, Gurcan MN. Digital pathology and artificial intelligence. Lancet Oncol. 2019;20(5):e253–e261. doi:10.1016/S1470-2045(19)30154-8
   PubMed Web of Science ®Google Scholar
• Ehteshami Bejnordi B, Veta M, Johannes van Diest P, et al. Diagnostic assessment of deep learning algorithms for detection of lymph node metastases in women with breast cancer. JAMA. 2017;318(22):2199–2210. doi:10.1001/jama.2017.14585
   PubMed Web of Science ®Google Scholar
• Kelly CJ, Karthikesalingam A, Suleyman M, Corrado G, King D. Key challenges for delivering clinical impact with artificial intelligence. BMC Med. 2019;17(1):195. doi:10.1186/s12916-019-1426-2
   PubMed Web of Science ®Google Scholar
• Abels E, Pantanowitz L, Aeffner F, et al. Computational pathology definitions, best practices, and recommendations for regulatory guidance: a white paper from the digital pathology association. J Pathol. 2019;249(3):286–294. doi:10.1002/path.5331
   PubMed Web of Science ®Google Scholar